Search 

A joint venture with AstraZeneca, focusing on introducing life science companies into Wuxi and develop the biopharmaceutical industry in the city.

focus on CVD, oncology，immunology

healthcare VC

2nd market PE,
about 300M RMB total value,
mainly focus on A-share market and startup on H-share market,
concentrating on high-speed developing industrials especially in Healthcare, including Big Biopharma/Superior Biotech companies.

Zhejiang Jianfeng Pharmaceutical Co., Ltd., founded on Dec. 30th, 1998, is a wholly-owned subsidiary of listed company Zhejiang Jianfeng Group Co., Ltd. (SHA: 600668). 　　Our company consists of five industrial enterprises, three commercial enterprises, three scientific institutions and two mobile postdoctoral stations. It is one of National Top 100 Pharmaceutical Enterprises, one of Top 10 Pharmaceutical Industrial Enterprises of Zhejiang Province, National Key High-tech Enterprise, National high-tech Industrialization Demonstration Project Enterprise, Innovative Demonstration Enterprise of Zhejiang Province, and AAA-level Contract-honoring and Promise-keeping Enterprise of Zhejiang Province.

Our key products include Aspartic Acid Amlodipine Tablets, Aceclofenac Sustained-release Tablets, Paroxetine Hydrochloride Tablets, Cefmenoxime Hydrochloride for Injection, Yufeng Ningxin Drop Pills, Penciclovir for Injection, Sodium Hyaluronate Eye Drops, and etc.

Adhering to the corporate spirit of “Aiming for Top One, Producing Fine Medicine”, pursuing business philosophy of “science and technology achieve health”, our company has been oriented by the development of bulk pharmaceutical chemicals with high technology content and high-added value, and new chemical medicine preparations and aided by the natural products extraction and proprietary Chinese medicine preparations. Meanwhile, our company is paying attention to the development method of new biological agent medicine, and will enter into the health product field in good time. We now have a main line with three major series products, which are anti-infection medicine, cardiovascular medicine, and anti-depression medicine. Depending on first-rate business philosophy, first-rate production management and first-rate products, our company will create a famous brand that is trusted by the public, and contribute to the health of human.

Zhongyuan Yuzi is a provincial investment company and a province-managed state-owned corporation, the establishment of which is approved by Henan provincial government, with the function of serving the strategy and market operation and the role in safeguarding the investment of provincial infrastructure projects,cultivating and guiding the strategic emerging industries, leading and inciting the social investments.

Currently, we are looking for leading pharmaceutical companies as long-term financial or strategic investment partnerships.

河南省骨干企业。先后发起设立了3000亿元规模的河南省新型城镇化发展基金、1000亿元规模的“一带一路（河南）发展基金”、 1000亿元规模的全省现代服务业基金、50亿元规模的PPP开发性基金。

截至2019年12月底，豫资控股集团注册资金100亿元，合并总资产2734.9亿，净资产845.57亿。豫资控股集团子公司及孙公司（并表子公司）共计67家，其中二级子公司11家，三级子公司56家。国内评级AAA、国际评级A2。

为终端医疗机构提供创新共赢的治疗解决方案
与推动行业发展的合作伙伴一道,整合医疗行业资源,探索创新业务体系,为终端医疗机构提供创新共赢的治疗解决方案辅助客户优化内部结构和管理,更好的服务于医疗终端和广大患者……
产品：血管外科腔内治疗“精准治疗辅助系统、放疗科癌症后装放疗“精准放疗辅助系统。

康为同创集团成立于2006年，位于北京市密云区经济开发区内，主要从事特种传动设备、电机电气、高端智能装备、智能传感器、智能芯片等的研发、生产、制造，是集产、学、研于一体的大型智能生产制造企业。产品广泛应用于轨道交通、商用航空器、基础工业、智能城市等诸多领域。

企业从成立之日起始终秉承“用户第一、质量第一、信誉第一、智能第一、双赢第一”的原则。已成功申请为国家高新技术企业，并取得国际铁路行业IRIS认证证书。集团公司经多年发展已初步建立起以智能设计为先导的智能化生产制造企业。为适应智能事业的需要，集团公司不断为客户提高更优质的服务。

专注于儿科品种

generic pharmaceutical listed company